A detailed history of Intech Investment Management LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Intech Investment Management LLC holds 19,832 shares of RCUS stock, worth $398,028. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,832
Previous 34,402 42.35%
Holding current value
$398,028
Previous $280,000 3.93%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 10, 2025

SELL
$8.22 - $13.6 $119,765 - $198,152
-14,570 Reduced 42.35%
19,832 $269,000
Q2 2025

Aug 08, 2025

SELL
$6.87 - $10.03 $33,717 - $49,227
-4,908 Reduced 12.49%
34,402 $280,000
Q1 2025

May 20, 2025

BUY
$7.85 - $15.24 $103,266 - $200,482
13,155 Added 50.3%
39,310 $308,000
Q4 2024

Feb 10, 2025

BUY
$14.28 - $18.44 $145,598 - $188,014
10,196 Added 63.89%
26,155 $389,000
Q3 2024

Nov 08, 2024

BUY
$13.69 - $18.01 $218,478 - $287,421
15,959 New
15,959 $244,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.45B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Intech Investment Management LLC Portfolio

Follow Intech Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Intech Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Intech Investment Management LLC with notifications on news.